Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination

Clinical and Vaccine Immunology

Volumn 20, Issue 2, 2013, Pages 269-275

  Yao, Qing Qing ^a   Dong, Xiao Lian ^b   Wang, Xue Cai ^b   Ge, Sheng Xiang ^c   Hu, An Qun ^d   Liu, Hai Yan ^d   Wang, Yueping Alex ^e   Yuan, Quan ^c   Zheng, Ying Jie ^a  

^a FUDAN UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Deqing County   (China)

^c XIAMEN UNIVERSITY   (China)

^d Anqing City Municipal Hospital   (China)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; GLUTAMIC ACID; GLUTAMINE; HEPATITIS B SURFACE ANTIGEN; LYSINE; RECOMBINANT HEPATITIS B VACCINE; TYROSINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POPULATION RESEARCH; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; VACCINATION; VERTICAL TRANSMISSION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; BASE SEQUENCE; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOTHERS; PHYLOGENY; PREGNANCY; QUESTIONNAIRES; SEQUENCE ANALYSIS, DNA; VACCINATION;

EID: 84874889350     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00539-12     Document Type: Article

References (38)

1. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11:97-107.
2. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. 2009. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 27:6550-6557.
3. Zhou YH, Wu C, Zhuang H. 2009. Vaccination against hepatitis B: the Chinese experience. Chin. Med. J. (Engl). 122:98-102.
4. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. 2006. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332:328-336.
5. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F. 2008. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49:652-657.
6. Raimondo G, Pollicino T, Romano L, Zanetti AR. 2010. A 2010 update on occult hepatitis B infection. Pathol. Biol. (Paris) 58:254-257.
7. El Chaar M, Candotti D, Crowther RA, Allain JP. 2010. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 52:1600-1610.
8. Gerlich WH, Bremer C, Saniewski M, Schuttler CG, Wend UC, Willems WR, Glebe D. 2010. Occult hepatitis B virus infection: detection and significance. Dig. Dis. 28:116-125.
9. Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, Ge SX, Zhang J, Xia NS. 2012. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J. Hepatol. 57:720-729.
10. Zuckerman JN, Zuckerman AJ. 2003. Mutations of the surface protein of hepatitis B virus. Antiviral Res. 60:75-78.
11. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. 2001. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 34:194-203.
12. Allain JP. 2004. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 86:83-91.
13. Chan HL, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, Chan FK, Sung JJ. 2002. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am. J. Gastroenterol. 97: 1211-1215.
14. Di Stefano M, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D, Pastore G, Gesualdo L, Fiore JR. 2009. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J. Nephrol. 22:381-386.
15. Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, Marchiaro G, Salizzoni M, Rizzetto M. 2004. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl. 10:356-362.
16. Gupta S, Singh S. 2010. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect. Dis. 10:53. doi:10.1186/1471-2334-10-53.
17. Ozaslan E, Demirezer A, Yavuz B. 2009. Occult hepatitis B virus infection in Turkish healthy individuals. Eur. J. Gastroenterol. Hepatol. 21: 1436-1437.
18. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T. 2008. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J. Hepatol. 48:743-746.
19. Samal J, Kandpal M, Vivekanandan P. 2012. Molecular mechanisms underlying occult hepatitis B virus infection. Clin. Microbiol. Rev. 25: 142-163.
20. Torbenson M, Thomas DL. 2002. Occult hepatitis B. Lancet Infect. Dis. ii:479-486.
21. Yuan Q, Ou SH, Chen CR, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AE, Shih JW, Zhang J, Xia NS. 2010. Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. J. Clin. Microbiol. 48:357-362.
22. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. 2009. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 200:1390-1396.
23. Giles ML, Visvanathan K, Lewin SR, Sasadeusz J. 2012. Chronic hepatitis B infection and pregnancy. Obstet. Gynecol. Surv. 67:37-44.
24. Chen WN, Oon CJ. 2000. Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high antihepatitis B virus antibody levels but negative for HBsAg. J. Clin. Microbiol. 38:2793-2794.
25. Mu SC, Lin YM, Jow GM, Chen BF. 2009. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J. Hepatol. 50:264-272.
26. Xu L, Wei Y, Chen T, Lu J, Zhu CL, Ni Z, Huang F, Du J, Sun Z, Qu C. 2010. Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination. Vaccine 28:5986-5992.
27. Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. 2012. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J. Hepatol. 57:515-521.
28. Taheri H, Hasanjani Roushan MR, Soleimani Amiri MJ, Pouralijan M, Bijani A. 2011. Efficacy of hepatitis B vaccine in those who lost hepatitis B surface antigen during follow-up: efficacy of HBV vaccine in those who lost HBsAg. Hepat. Mon. 11:119-122.
29. Wang FD, Huang BD, Liu XH, Wu QW, Wang XL, Wang XC. 1999. The efficacy of recombinant hepatitis B vaccine on the blocking of mother-to-infant transmission. Zhejiang Prev. Med. 11:19-20.
30. Magnius LO, Norder H. 1995. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 38:24-34.
31. Zheng Y, Ge S, Zhang J, Guo Q, Ng MH, Wang F, Xia N, Jiang Q. 2006. Swine as a principal reservoir of hepatitis E virus that infects humans in eastern China. J. Infect. Dis. 193:1643-1649.
32. Chang MH. 2006. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J. Clin. Virol. 36(Suppl 1):S45-S50.
33. Ranger-Rogez S, Denis F. 2004. Hepatitis B mother-to-child transmission. Expert Rev. Anti Infect. Ther. 2:133-145.
34. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. 1998. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J. Pediatr. 133:374-377.
35. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O'Malley PM, Penley KA, Altman NL, Braff E, Shipman GF, Coleman PJ, Mandel EJ. 1986. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N. Engl. J. Med. 315:209-214.
36. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, Wang SS, Li YP, Zhang KL. 1999. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 17:2661-2666.
37. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. 2010. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 28: 623-631.
38. Kwon CI, Hwang SG, Shin SJ, Chang SW, Kim SY, Ko KH, Hong SP, Park PW, Rim KS, Kang MS, Chung HJ. 2008. Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int. 28: 667-674.